Glenmark-Celon Generic Seretide DPI On Its Way In Europe
Executive Summary
Glenmark-Celon’s generic Seretide Accuhaler dry powder inhaler (DPI) appears on course for a debut in Europe, piling up more pressure on GlaxoSmithKline’s respiratory franchise. Substitutability of the generic, however, will be key to driving momentum in uptake.
You may also be interested in...
Will Glenmark-Celon’s ‘Substitutable’ Seretide Deliver In Europe?
Glenmark-Celon’s generic Seretide Accuhaler dry powder inhaler (DPI) has hit the Danish market but whether it can build momentum around its regulatory clearance for substitution remains to be seen.
Will Glenmark-Celon’s ‘Substitutable’ Seretide Deliver In Europe?
Glenmark-Celon’s generic Seretide Accuhaler dry powder inhaler (DPI) has hit the Danish market but whether it can build momentum around its regulatory clearance for substitution remains to be seen.
Seretide Competition Builds Up But Substitutability Holds Key?
More possible competition is building for GlaxoSmithKline's blockbuster salmeterol and fluticasone combination, with a second Indian firm teaming up with the Polish biopharmaceutical company Celon to produce a version of the product.